Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its target price dropped by stock analysts at JPMorgan Chase & Co. from $177.00 to $175.00 in a report released on Friday, Benzinga reports. The firm presently has an "overweight" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s price target suggests a potential upside of 30.93% from the company's current price.
Other equities research analysts have also issued reports about the stock. TheStreet raised shares of Sarepta Therapeutics from a "d" rating to a "c-" rating in a report on Monday, March 4th. Citigroup increased their target price on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a "buy" rating in a report on Thursday, February 29th. Royal Bank of Canada increased their target price on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an "outperform" rating in a report on Thursday, February 29th. Evercore ISI increased their price objective on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an "in-line" rating in a report on Tuesday, February 20th. Finally, Wedbush reaffirmed an "outperform" rating and set a $224.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $160.60.
Read Our Latest Stock Report on Sarepta Therapeutics
Sarepta Therapeutics Stock Performance
Shares of NASDAQ SRPT traded up $3.03 during midday trading on Friday, hitting $133.66. 1,196,283 shares of the company's stock traded hands, compared to its average volume of 1,017,739. Sarepta Therapeutics has a 1 year low of $55.25 and a 1 year high of $159.89. The stock has a market capitalization of $12.63 billion, a price-to-earnings ratio of -21.84 and a beta of 0.95. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95. The firm has a fifty day moving average of $125.69 and a 200 day moving average of $110.70.
Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating the consensus estimate of ($0.11) by $0.84. The firm had revenue of $413.50 million during the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.32%. The business's revenue for the quarter was up 63.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.44) EPS. On average, analysts forecast that Sarepta Therapeutics will post 2.13 earnings per share for the current year.
Insider Buying and Selling
In related news, insider Bilal Arif sold 2,000 shares of the firm's stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the sale, the insider now directly owns 26,836 shares in the company, valued at $3,457,550.24. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the sale, the insider now owns 26,836 shares in the company, valued at $3,457,550.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the sale, the director now owns 7,516 shares in the company, valued at approximately $923,941.88. The disclosure for this sale can be found here. Insiders sold a total of 22,096 shares of company stock worth $2,739,419 over the last three months. 7.40% of the stock is owned by insiders.
Institutional Trading of Sarepta Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in shares of Sarepta Therapeutics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company's stock valued at $1,039,212,000 after purchasing an additional 41,465 shares in the last quarter. Picton Mahoney Asset Management acquired a new stake in Sarepta Therapeutics in the third quarter valued at approximately $2,576,000. WCM Investment Management LLC acquired a new stake in Sarepta Therapeutics in the fourth quarter valued at approximately $600,000. Capula Management Ltd acquired a new stake in Sarepta Therapeutics in the third quarter valued at approximately $1,409,000. Finally, State of New Jersey Common Pension Fund D grew its holdings in Sarepta Therapeutics by 8.2% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 51,398 shares of the biotechnology company's stock valued at $4,956,000 after purchasing an additional 3,912 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.
Sarepta Therapeutics Company Profile
(
Get Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sarepta Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.
While Sarepta Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
